China deals trump "compulsory license" card for domestic manufacturers

Coming at a time when pharmas have committed huge amounts of investments to establish manufacturing, R&D, and strategic business units in the country in response to its increasingly reliable intellectual property (IP) laws and reinforcement, China dealt a wild card sure to set alarm bells ringing. C...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

New insights about human immune response to COVID-19 have implications for vaccine design against new variants

News Commentary | May 07, 2021

Multiple new and emerging COVID‑19 variants with higher transmission rates have thrown into question the continued efficacy of existing vaccines across these newer strains. Previous research has focused on the receptor‑binding domain (RBD) given its importance in attaching to and infecting human ... To read more, click here.

Insurers decline to cover Biogen's new Alzheimer's disease (AD) drug as the fallout continues from the FDA's controversial approval

News Commentary | July 19, 2021

Biogen's AD drug, Aduhelm, continues to stir controversy, as several private insurers have decided not to cover the high costs of the medication. This includes some affiliates of Blue Cross Blue Shield and even the CMS, despite the FDA's accelerated approval. With pharmaceuticals like Roche and Eli ... Not part of subscription

Google-backed Calico and AbbVie announce second extension of a long-standing partnership to tackle aging-related diseases

News Commentary | July 30, 2021

Google‑backed Calico and pharma giant AbbVie are doubling down on tackling aging‑related diseases with this second partnership extension. Twenty early‑stage programs have been developed across oncology and neurodegeneration, with the lead oncology target, which acts at multiple steps in the cancer ... Not part of subscription